Plain-English translation of NCT06731673 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is investigating whether a protein called Heat Shock Protein 47 (HSP47) can be used as an early warning sign for blood clots and related conditions. Researchers will compare blood samples from people who have recently experienced a blood clot, heart attack, or stroke with samples from healthy volunteers to see if this protein is present at higher levels in those with these conditions.
Currently, doctors don't have a reliable way to predict who will develop dangerous blood clots or related conditions. If this protein can be identified as a marker, it could help doctors identify at-risk patients earlier and prevent serious complications.
You likely qualify if…
You likely don't qualify if…
If you have a blood clot, heart attack, or stroke, you'll give a blood sample when you're diagnosed, then again at 3 months and 12 months after diagnosis. Healthy volunteers will give a single blood sample. The study involves no medications or special procedures—just brief blood draws to measure protein levels.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
Denmark
Germany
Collaborators
Aarhus University Hospital, Max Planck Institute of Biochemistry
Enrollment target
~340 participants
Started
December 2024
Primary completion
August 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in August 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Kathrine A Friis, MD, PhD-fellow
University of Aarhus
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.